Ex vivo detectable human CD8 T-cell responses to cancer-testis antigens

Petra Baumgaertner, Nathalie Rufer, Estelle Devevre, Laurent Derre, Donata Rimoldi, Christine Geldhof, Verena Voelter, Danielle Liénard, Pedro Romero, Daniel E. Speiser*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

44 Scopus citations

Abstract

Clinical trials have shown that strong tumor antigen-specific CDS T-cell responses are difficult to induce but can be achieved for T-cells specific for melanoma differentiation antigens, upon repetitive vaccination with stable emulsions prepared with synthetic peptides and incomplete Freund's adjuvant. Here, we show in four melanoma patients that ex vivo detectable T-cells and thus strong T-cell responses can also be induced against the more universal cancer-testis antigens NY-ESO-1 and Mage-A10. Interestingly, all patients had ex vivo detectable T-cell responses against multiple antigens after serial vaccinations with three peptides emulsified in incomplete Freund's adjuvant. Antigen-specific T-cells displayed an activated phenotype and secreted IFNγ. The robust immune responses provide a solid basis for further development of human T-cell vaccination.

Original languageEnglish (US)
Pages (from-to)1912-1916
Number of pages5
JournalCancer Research
Volume66
Issue number4
DOIs
StatePublished - Feb 15 2006
Externally publishedYes

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Ex vivo detectable human CD8 T-cell responses to cancer-testis antigens'. Together they form a unique fingerprint.

Cite this